Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 10/20 | 0.57 |
| ▸ | MAPT | P10636 | 7/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.57 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 9/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | STAT1 | P42224 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5742108 | 0.98 | ALDH1A1 (0.69) | ALDH1A1HDAC6RAB9AMAPTKMT2A | |
| SCHEMBL20897465 | 0.96 | ALDH1A1 (0.71) | ALDH1A1HDAC6RAB9AMAPTKMT2A | |
| SCHEMBL7341735 | 0.91 | ALDH1A1 (0.60) | ALDH1A1HDAC6RAB9AMAPTKMT2A | |
| SCHEMBL20898181 | 0.90 | ALDH1A1 (0.63) | ALDH1A1HDAC6RAB9AMAPTKMT2A | |
| SCHEMBL21371829 | 0.88 | TSHR (0.58) | ALDH1A1RAB9AMAPTKMT2ANPC1 | |
| SCHEMBL64153 | 0.87 | ALDH1A1 (0.64) | ALDH1A1RAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL65696 | 0.86 | ALDH1A1 (0.71) | ALDH1A1RAB9AMAPTKMT2ANPC1 | |
| SCHEMBL1063179 | 0.86 | ALDH1A1 (0.67) | ALDH1A1HDAC6RAB9AMAPTKMT2A | |
| SCHEMBL22513663 | 0.85 | ALDH1A1 (0.55) | ALDH1A1HDAC6RAB9AMAPTKMT2A | |
| SCHEMBL10861127 | 0.85 | ALDH1A1 (0.65) | ALDH1A1RAB9AMAPTKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020168017-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | AMBRX, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| US-10274874-B2 | Intermediate transfer member, method for producing intermediate transfer member, and image forming apparatus | Konica Minolta, Inc. (JP) | 2019-04-30 | — | — | US | disclosed |
| US-20180136590-A1 | INTERMEDIATE TRANSFER MEMBER, METHOD FOR PRODUCING INTERMEDIATE TRANSFER MEMBER, AND IMAGE FORMING APPARATUS | Konica Minolta, Inc. (JP) | 2018-05-17 | — | — | US | disclosed |
| US-20180136590-A1 | INTERMEDIATE TRANSFER MEMBER, METHOD FOR PRODUCING INTERMEDIATE TRANSFER MEMBER, AND IMAGE FORMING APPARATUS | Konica Minolta, Inc. (JP) | 2018-05-17 | — | — | US | disclosed |
| EP-2233469-B1 | Method for coupling halogen-substituted aromatic substances with trialkylsilyl-substituted heteroatom-containing organic compounds | ZYLUM BETEILIGUNGSGMBH & CO PATENTE II KG (DE) | 2012-07-18 | — | — | EP | disclosed |
| US-20120142937-A1 | METHOD FOR COUPLING HALOGEN-SUBSTITUTED AROMATIC COMPOUNDS WITH ORGANIC COMPOUNDS COMPRISING TRIALKYLSILYL-SUBSTITUTED HETEROATOMS | ZYLUM BETEILIGUNGSGESELLSCHAFT MBH & CO. PATENTE II KG (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142937-A1 | METHOD FOR COUPLING HALOGEN-SUBSTITUTED AROMATIC COMPOUNDS WITH ORGANIC COMPOUNDS COMPRISING TRIALKYLSILYL-SUBSTITUTED HETEROATOMS | ZYLUM BETEILIGUNGSGESELLSCHAFT MBH & CO. PATENTE II KG (DE) | 2012-06-07 | — | — | US | disclosed |
| EP-2233469-A1 | Method for coupling halogen-substituted aromatic substances with trialkylsilyl-substituted heteroatom-containing organic compounds | Zylum Beteiligungsgesellschaft mbH & Co. Patente II KG (DE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010106078-A1 | METHOD FOR COUPLING HALOGEN-SUBSTITUTED AROMATIC COMPOUNDS WITH ORGANIC COMPOUNDS COMPRISING TRIALKYLSILYL-SUBSTITUTED HETEROATOMS | ZYLUM BETEILIGUNGSGESELLSCHAFT MBH & CO. PATENTE II KG (DE) | 2010-09-23 | — | — | WO | disclosed |
| US-7754886-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1358183-B1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1318978-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20050070598-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2005-03-31 | — | — | US | disclosed |
| US-20040229915-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2004-11-18 | — | — | US | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| EP-1358183-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| US-20030186962-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
| WO-2002088106-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2002-11-07 | — | — | WO | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | ALDH1A1 2651/4885HDAC6 803/4885RAB9A 4211/4885 |
| US-20030186962-A1 | Cysteine protease inhibitors | C1R, CTSS, CTSZ | ALDH1A1 3348/4885HDAC6 215/4885RAB9A 454/4885 |
| US-20050070598-A1 | Cysteine protease inhibitors | CTRL, CTSZ, CTSS | ALDH1A1 3475/4885HDAC6 162/4885RAB9A 1291/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | ALDH1A1 2460/4885HDAC6 578/4885RAB9A 3769/4885 |
| US-20120142937-A1 | METHOD FOR COUPLING HALOGEN-SUBSTITUTED AROMATIC COMPOUNDS WITH ORGANIC COMPOUNDS COMPRISING TRIALKYLSILYL-SUBSTITUTED HETEROATOMS | TYR, ALK, TTL | ALDH1A1 2734/4885HDAC6 3256/4885RAB9A 1260/4885 |
| US-20040229915-A1 | Cysteine protease inhibitors | C1R, CTRL, CTSK | ALDH1A1 3118/4885HDAC6 291/4885RAB9A 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.